Literature DB >> 20218931

Itk inhibitors: a patent review.

Ho Yin Lo1.   

Abstract

UNLABELLED: Importance of field: IL-2 inducible T-cell kinase (Itk) is a non-receptor tyrosine kinase of the Tec family. It plays an important role in T cell signaling and the production of various pro-inflammatory cytokines such as IL-2, IL-4, IL-5, IL-10 and IL-13. Inhibition of Itk has been a target for the treatment of diseases related to inflammation disorders such as psoriasis and allergic asthma. Rich resources on the structural information for Itk made discovery of novel selective Itk inhibitors blossom in the past decade. AREAS COVERED IN THIS REVIEW: In this report, distinct structural classes of specific Itk inhibitors are summarized and their in vitro/in vivo properties are discussed. WHAT THE READER WILL GAIN: A summary of 21 patents including 16 different chemical structure classes of Itk inhibitors. The in vivo efficacies of some of the inhibitors in animal models are also discussed. TAKE HOME MESSAGE: Although some of the inhibitors show efficacy in different animal models, which implies potential for therapeutic use in human, there is not yet a chemical entity reported in clinical trials. The prospects for Itk inhibitors will rely on the quality of the compound and the validity of the target in patients within the selected therapeutic area.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20218931     DOI: 10.1517/13543771003674409

Source DB:  PubMed          Journal:  Expert Opin Ther Pat        ISSN: 1354-3776            Impact factor:   6.674


  9 in total

1.  A unique role for ITK in survival of invariant NKT cells associated with the p53-dependent pathway in mice.

Authors:  Qian Qi; Weishan Huang; Yuting Bai; Gabriel Balmus; Robert S Weiss; Avery August
Journal:  J Immunol       Date:  2012-03-07       Impact factor: 5.422

2.  IL2 Inducible T-cell Kinase, a Novel Therapeutic Target in Melanoma.

Authors:  Craig C Carson; Stergios J Moschos; Sharon N Edmiston; David B Darr; Nana Nikolaishvili-Feinberg; Pamela A Groben; Xin Zhou; Pei Fen Kuan; Shaily Pandey; Keefe T Chan; Jamie L Jordan; Honglin Hao; Jill S Frank; Dennis A Hopkinson; David C Gibbs; Virginia D Alldredge; Eloise Parrish; Sara C Hanna; Paula Berkowitz; David S Rubenstein; C Ryan Miller; James E Bear; David W Ollila; Norman E Sharpless; Kathleen Conway; Nancy E Thomas
Journal:  Clin Cancer Res       Date:  2015-05-01       Impact factor: 12.531

3.  Treatment of Immunological or Inflammatory Disorders with ITK Kinase Inhibitors.

Authors:  Ahmed F Abdel-Magid
Journal:  ACS Med Chem Lett       Date:  2014-03-06       Impact factor: 4.345

4.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Authors:  Jason A Dubovsky; Kyle A Beckwith; Gayathri Natarajan; Jennifer A Woyach; Samantha Jaglowski; Yiming Zhong; Joshua D Hessler; Ta-Ming Liu; Betty Y Chang; Karilyn M Larkin; Matthew R Stefanovski; Danielle L Chappell; Frank W Frissora; Lisa L Smith; Kelly A Smucker; Joseph M Flynn; Jeffrey A Jones; Leslie A Andritsos; Kami Maddocks; Amy M Lehman; Richard Furman; Jeff Sharman; Anjali Mishra; Michael A Caligiuri; Abhay R Satoskar; Joseph J Buggy; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2013-07-25       Impact factor: 22.113

5.  Identification of a Novel and Selective Series of Itk Inhibitors via a Template-Hopping Strategy.

Authors:  Catherine M Alder; Martin Ambler; Amanda J Campbell; Aurelie C Champigny; Angela M Deakin; John D Harling; Carol A Harris; Tim Longstaff; Sean Lynn; Aoife C Maxwell; Chris J Mooney; Callum Scullion; Onkar M P Singh; Ian E D Smith; Donald O Somers; Christopher J Tame; Gareth Wayne; Caroline Wilson; James M Woolven
Journal:  ACS Med Chem Lett       Date:  2013-08-12       Impact factor: 4.345

6.  Discovery of potent inhibitors for interleukin-2-inducible T-cell kinase: structure-based virtual screening and molecular dynamics simulation approaches.

Authors:  Chandrasekaran Meganathan; Sugunadevi Sakkiah; Yuno Lee; Jayavelu Venkat Narayanan; Keun Woo Lee
Journal:  J Mol Model       Date:  2012-09-27       Impact factor: 1.810

Review 7.  Signal transduction via the T cell antigen receptor in naïve and effector/memory T cells.

Authors:  Arun Kannan; Weishan Huang; Fei Huang; Avery August
Journal:  Int J Biochem Cell Biol       Date:  2012-09-04       Impact factor: 5.085

8.  Identification of Hub Genes and Pathways of Triple Negative Breast Cancer by Expression Profiles Analysis.

Authors:  Liqi Li; Hu Huang; Mingjie Zhu; Junqiang Wu
Journal:  Cancer Manag Res       Date:  2021-03-01       Impact factor: 3.989

Review 9.  Role of the IL-2 inducible tyrosine kinase ITK and its inhibitors in disease pathogenesis.

Authors:  Kristina S Lechner; Markus F Neurath; Benno Weigmann
Journal:  J Mol Med (Berl)       Date:  2020-08-18       Impact factor: 4.599

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.